ArticleInternational journal of general medicine2025
Relationship Between MIC-1, VEGF, and TGF-β1 and Clinicopathologic Stage and Lymph Node Metastasis in Gastric Cancer.
Article in International journal of general medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This research investigated the relationship between serum macrophage inhibitory cytokine-1 (MIC-1), vascular endothelial growth factor (VEGF), and transforming growth factor-β1 (TGF-β1) levels and clinicopathologic features, lymph node metastasis (LNM), and prognosis of gastric cancer (GC) patients. Methods: The GC group (GC patients, 198 cases)) and healthy group (healthy people, 100 cases) were established. The relationship between serum MIC-1, VEGF, TGF-β1, and clinical and pathological features in GC patients was analyzed. GC patients were divided into a metastasis group (77 patients) and a non-metastasis group (121 patients) based on whether they had LNM. The factors influencing LNM in GC patients were identified. The predictive value of serum MIC-1, VEGF, and TGF-β1 for LNM in GC patients and the relationship between serum MIC-1, VEGF, TGF-β1 levels and prognosis were analyzed. Results: MIC-1, VEGF, and TGF-β1 were higher in GC. Serum MIC-1, VEGF, and TGF-β1 levels were higher in GC patients with tumor diameter ≥ 3 cm, T stage of T3 and T4, low/moderate differentiation, and LNM. Multivariate Logistic regression analysis showed that TNM stage, tumor differentiation, and serum MIC-1, VEGF, and TGF-β1 levels were risk factors for LNM in GC patients. The ROC results indicated that the combination of serum MIC-1, VEGF, and TGF-β1 had the highest AUC for predicting LNM in GV patients. The median survival time of patients with low serum MIC-1, VEGF, and TGF-β1 was higher than that of patients with high serum MIC-1, VEGF, and TGF-β1 (26.13 months vs 19.24 months, 27.06 months vs 20.18 months, and 24.20 months vs 20.08 months). Conclusion: The changes of serum MIC-1, VEGF and TGF-β1 levels are related to the clinicopathological characteristics of GC patients, and the elevated levels of these indices are independent risk factors affecting LNM and prognosis of GC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.